Trending Topics
Zoll header_$.png

Nationwide, communities continue to battle the effects of the opioid crisis. Litigation brought by states against drug distributors, manufacturers and pharmacy chains has produced opioid settlement funding designed to bring relief to communities affected by the epidemic. The various funding mechanisms (how to request, how to apply and to who) is evolving and varies by state.

First responders are on the front line of this crisis treating overdose patients, securing illegal, dangerous drugs and managing the various scenarios related to opioid calls. For public safety agencies, including EMS, opioid settlement funding may be tapped for a variety of purposes. For this reason, public safety leaders must understand the basics of the settlements, how funds will be distributed and how your agency may be able to tap into funding in a responsible manner.

Follow our Opioid Settlement Funding: Compensation For Communities coverage, brought to you by ZOLL Medical, to stay informed.

Related news about the opioid crisis and improving patient outcomes
Last year, the opioid toll rose to nearly 19,000 deaths, an increase of 16 percent
Quantitative waveform capnography can help EMS providers recognize bronchospasm, spot ventilation derangements, and gauge the effectiveness of therapy
The man crashed his car into the jail’s front doors and then into the fence outside the building
Show off your mastery of CPR with this 10-question quiz of what every EMT should know about basic life support
Health care practitioners challenged to think outside the box to understand and solve the problem of out-of-hospital cardiac arrest
Here’s why locking the ambulance should be a policy for every agency and a habit for every EMS provider, like wearing a seatbelt
Alameda County, California, says they’ve found the “prescription for success” in improving cardiac arrest outcomes
Dr. Tom Rea Emergency Cardiovascular Care Update 2015 opening session challenged attendees to improve cardiac arrest survival in their community
The clinical trial aims to prove whether the drug is a viable option to reduce excess bleeding from traumatic brain injuries
About the Sponsor: ZOLL
ZOLL is a resuscitation solutions pioneer, distinguished by consistency in management, ownership, and approach for nearly 30 years. As a financially strong, public company, ZOLL has an enviable product quality and reliability record. ZOLL technologies to help advance the practice of resuscitation include pacing, defibrillation, circulation, ventilation, data management, and fluid resuscitation.

These comprehensive technologies help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest and trauma victims. ZOLL’s commitment is to be the dependable choice for all providers in the field of resuscitation.

ZOLL markets and sells its products, including AED Plus®, AED Pro®, the R Series™ defibrillator, the AutoPulse® non-invasive cardiac support pump, and the LifeVest® wearable defibrillator in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia.